BiomX Announces $3.0 Million Private Placement
Rhea-AI Summary
BiomX (NYSE American: PHGE) announced a private placement expected to raise approximately $3.0 million in gross proceeds on December 29, 2025. The company said proceeds will support assessment of opportunities to advance BX011 and continued evaluation of strategic alternatives. H.C. Wainwright & Co. served as exclusive placement agent. Amounts are before placement agent fees and offering expenses.
Positive
- $3.0 million expected gross proceeds
- Proceeds designated to advance BX011 assessment
- Funds to support evaluation of strategic alternatives
Negative
- Gross proceeds are before placement agent fees and offering expenses
- Private placement may cause shareholder dilution
Market Reaction 15 min delay 2 Alerts
Following this news, PHGE has gained 7.05%, reflecting a notable positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $2.07. This price movement has added approximately $208K to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus 1 Up 1 Down
PHGE was down 3.5% pre-news while peers were mixed: APLM up 17.65%, ADAP down 17.57%, PHIO and APM modestly positive and BIVI negative. Momentum scanner also showed BCDA up 7.87% and BIVI down 4.96%, supporting a stock-specific, not sector-wide, move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Trial discontinuation | Negative | -36.9% | Ended BX004 Phase 2b after safety concerns and resource constraints. |
| Nov 25 | Clinical trial update | Neutral | +5.4% | FDA device review and adjusted dosing with BX004 topline timing update. |
| Nov 14 | Reverse stock split | Neutral | +7.5% | Announced 1-for-19 reverse split and share-count reduction details. |
| Nov 12 | Earnings and updates | Neutral | -1.9% | Reported Q3 2025 results, limited cash and clinical program timelines. |
| Nov 05 | Earnings preview | Neutral | +2.0% | Scheduled Q3 2025 results call and program update webcast. |
Price reactions have generally aligned with news tone, with a sharp -36.94% selloff on negative BX004 discontinuation news and modest moves on neutral operational and financial updates.
Over the past few months, BiomX has faced mounting challenges. On Nov 12, 2025, Q3 results highlighted limited cash of $8.1M and losses while advancing BX004 and BX011. A 1-for-19 reverse split announced on Nov 14 preceded continued operational updates on BX004. The decisive negative turn came on Dec 8 with discontinuation of the BX004 Phase 2b trial, which triggered a -36.94% drop. Today’s $3.0M private placement follows these liquidity and strategic pressures.
Market Pulse Summary
The stock is up +7.0% following this news. A strong positive reaction aligns with the company’s urgent need for capital after limited cash of $8.069M and a prior -36.94% drop on BX004 discontinuation. The announced $3.0M private placement would modestly extend runway for BX011 and strategic reviews. However, past operating cash use of $22.004M over nine months and recent insolvency proceedings at a subsidiary highlight balance-sheet risk that could cap longer-term enthusiasm.
Key Terms
private investment in public equity financial
private placement financial
AI-generated analysis. Not financial advice.
Proceeds to Support the Company’s Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic Alternatives
NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity (“Private Placement”) financing for expected gross proceeds of approximately
H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement.
About the Private Placement
In the Private Placement, the Company agreed to issue and sell shares of its Series Y Convertible Preferred Stock, with a stated value of
Each share of Series Y Convertible Preferred Stock will accrue dividends at a rate of
In connection with the Private Placement, the Company will also issue warrants to acquire up to 3,300,000 shares of the Company’s common stock. The warrants will have a five-year term and an exercise price initially equal to
The Private Placement is expected to close on or about December 30, 2025, subject to the satisfaction of customary closing conditions.
The Securities sold in the Private Placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws, and were offered and sold in reliance on exemptions from the registration requirements of the Securities Act. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issuable upon conversion of the Series Y Convertible Preferred Stock and exercise of the warrants.
The Company intends to use the net proceeds from the private placement to support its assessment of opportunities across its bacteriophage programs, including BX011 for Staphylococcus aureus infections associated with diabetic foot infections, and for general corporate purposes, including providing operational flexibility while the Company continues to evaluate strategic alternatives.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any Securities, nor shall there be any sale of Securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
Safe Harbor
This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX refers to the anticipated closing of the Private Placement and timing thereof, the intended use of the net proceeds, the receipt of stockholder approval, the evaluation of opportunities related to its clinical programs, including BX011, the timing and design of potential future development activities, and its ongoing assessment of strategic alternatives, it is using forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX’s control. These risks and uncertainties include, but are not limited to, market and other conditions, BiomX’s ability to obtain all necessary regulatory approvals on a timely basis, or at all; BiomX’s ability to obtain stockholder approval on a timely basis, or at all; the closing of the private placement on a timely basis on the terms described herein, or at all; changes in applicable laws or regulations; the possibility that BiomX may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in BiomX’s drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials, BiomX’s ability to enroll patients in its clinical trials, and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the FDA and other regulatory authorities; investigational review boards at clinical trial sites and publication review bodies with respect to our development candidates; BiomX’s ability to obtain, maintain and enforce intellectual property rights for its platform and development candidates; its potential dependence on collaboration partners; competition; uncertainties as to the sufficiency of BiomX’s cash resources to fund its planned activities for the periods anticipated and BiomX’s ability to manage unplanned cash requirements; and general economic and market conditions. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2025, and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements.
Contacts:
BiomX, Inc.
Ben Cohen
Head Corporate Communications
benc@biomx.com
FAQ
What amount is BiomX (PHGE) expected to raise in the December 29, 2025 private placement?
What will BiomX (PHGE) use the private placement proceeds for?
Who acted as placement agent for BiomX's (PHGE) private placement?
Are the $3.0 million proceeds net of fees for BiomX (PHGE)?
Could BiomX's (PHGE) private placement affect existing shareholders?
When was the BiomX (PHGE) private placement announced?
